Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -36.72 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 753.36 | 60.12 | 15.62 | 61.29 | 55.54 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 159.73 | — | 11.39 | 6.58 | 2.64 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Abivax S.A.'s operating margin was -4645.3% in Q2 2025, down 2848.0 pp QoQ and down 2886.6 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -2899.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| — | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1602.9% | -4645.3% | -1797.3% | -1178.9% | -3975.2% | -1758.7% | -1726.1% | -836.0% | — | — | — | — | — |
| — | -164.1% | -4.1% | -41.0% | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1633.1% | -4996.7% | -1278.6% | -1203.0% | -4118.1% | -2311.1% | -1792.4% | -1326.4% | — | — | — | — | — |
| — | -116.2% | +28.7% | +9.3% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -149.0% | — | -113.3% | -25.3% | -69.3% | -118.5% | -607.3% | -184.6% | -175.4% | -163.1% | -160.9% | -109.4% | -83.3% |
| — | — | +81.4% | +86.3% | +60.5% | +27.3% | -277.4% | -68.8% | -110.5% | -219.7% | -610.4% | -573.9% | -629.8% | |
| ROA | -66.2% | -62.0% | -38.6% | -13.3% | -38.5% | -42.1% | -54.8% | -32.7% | -30.2% | -26.2% | -36.5% | -30.4% | -31.0% |
| — | -47.3% | +29.4% | +59.1% | -27.3% | -61.1% | -49.8% | -7.6% | +2.4% | -0.3% | -113.2% | -109.3% | -197.5% | |
| ROIC | — | — | -1774.9% | -305.7% | -4771.0% | -293.6% | -92.7% | -46.4% | -82.4% | -75.9% | -78.6% | -47.1% | -39.7% |
| — | — | -1814.2% | -559.4% | -5687.7% | -287.0% | -18.0% | +1.6% | -107.7% | -102.0% | -278.0% | -211.1% | -278.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 72.8% YoY to 0.77x, tightening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.40 | — | 2.40 | 0.90 | 0.30 | 0.43 | 5.45 | 8.04 | 1.99 | 13.40 | 1.90 | 2.55 | 1.12 |
| — | — | -56.0% | -88.8% | -85.1% | -96.8% | +186.8% | +215.3% | +78.5% | +1185.7% | +503.8% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.84 | 0.77 | 1.84 | 3.04 | 3.25 | 2.82 | 0.70 | 2.63 | 2.33 | 0.45 | 1.94 | 0.83 | 1.47 |
| — | -72.8% | +161.5% | +15.4% | +39.2% | +529.3% | -63.8% | +215.6% | +58.4% | -37.5% | -21.4% | -69.0% | -61.6% | |
| Quick Ratio | 1.84 | 0.77 | 1.84 | 3.04 | 3.25 | 2.82 | 0.70 | 2.63 | 2.21 | 0.45 | 1.94 | 0.83 | 1.38 |
| — | -72.8% | +161.5% | +15.4% | +47.0% | +529.3% | -63.8% | +215.6% | +60.0% | -37.5% | -21.4% | -69.0% | -64.1% | |
| Interest Coverage | -41.33 | -13.37 | -96.93 | -55.51 | -16.22 | -2.69 | -21.46 | -8.76 | -11.81 | -25.66 | -17.26 | -16.83 | -16.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAbivax S.A.'s current P/E is -36.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Abivax S.A.'s current operating margin is -1602.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Abivax S.A.'s business trajectory between earnings reports.